Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 20;37:233. doi: 10.1186/s13046-018-0873-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 6 — Cyclin D1 IHC in metastatic NPC clinical samples. (a) Cyclin D1 expression in a liver and a lung metastasized NPC patients. The Kaplan-Meier survival curves of the NPC patients classified by the (b) intensity and (c) percentage of positive cells in cyclin D1 IHC staining. A 46 year-old NPC patient with T4N2M0 (stage IVa), also a hepatitis B virus carrier, received concurrent chemoradiotherapy (CCRT) for local disease control. Liver metastasis (cyclin D1 staining, in Fig. 7a) was detected 9 months later and five different lines of palliative chemotherapy prescribed. Finally, the patient received palbociclib (PAL) as salvage treatment at Johns Hopkins Medicine, Singapore. (d) Plasma EBV DNA load reflecting the clinical treatment response of the patient was decreased after treatment with PAL. (e) Whole-body tumor scan before and after PAL treatment at 2-month intervals revealed stable disease. Abbreviations: PULB, (cisplatin, tegafur/uracil, leucovorin, and bleomycin); UFT, (tegafur/uracil); G + P, (gemcitabine + cisplatin); T + P, (docetaxel + cisplatin)